In re: McKinsey & Co., Inc. National Prescription Opiate Consultant Litigation

Track this case

Case Number:

3:21-md-02996

Court:

California Northern

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Charles R. Breyer

Firms

Companies

Government Agencies

Sectors & Industries:

March 06, 2023
Tribes And Others Fight To Keep McKinsey Opioid Suit Alive

Tribes, health insurance plans and children born with neonatal abstinence syndrome suing McKinsey & Co. for masterminding schemes to help Purdue Pharma LP and the Sackler family sell addictive opioids have urged a California federal judge to reject the management consultant's attempt to throw out their multidistrict litigation.
January 26, 2023
Ariz. Tribe Sues McKinsey Over Opioid Crisis

The White Mountain Apache Tribe on Wednesday hit McKinsey & Co. with a RICO suit over the firm's alleged role in the tribe's opioid epidemic in San Francisco federal court, claiming it aided opioid makers in executing a marketing strategy to boost sales of the addictive painkillers, joining a number of jurisdictions in the growing multidistrict litigation.
November 02, 2022
After Pharmacy Deals, New Opioid Sellers In Legal 'Bull's-Eye'

Multibillion-dollar settlements with top pharmacy retailers will shift a historic barrage of opioid litigation away from the last of its early targets and toward groups of pharmaceutical sellers and advisers whose business practices and legal defenses have received little attention, according to plaintiffs counsel and court records.
October 27, 2022
McKinsey Loses Opioid Dismissal Bid Amid Deal With Others

A California federal judge presiding over multidistrict opioid litigation denied McKinsey & Co.'s bid to toss claims by plaintiffs in 19 states Thursday, a day after the consulting firm and a group of school districts, cities and counties informed the court they had struck a settlement in the case.
April 13, 2022
Report Says McKinsey Hid Conflicts In Advising FDA, Purdue

Top McKinsey & Co. consultants were doing work with the U.S. Food and Drug Administration at the same time they were providing opioid marketing advice to Purdue Pharma LP and other drugmakers, federal lawmakers said in a new report that looked into alleged conflicts of interest.
March 31, 2022
$640M Question: 'What Did McKinsey Get' In Big Opioid Deal?

A California federal judge indicated Thursday that sprawling litigation targeting McKinsey & Co.'s opioid marketing advice will soon see its fate decided by a single thorny question: Were the legal grievances of thousands of local governments covered by the consulting firm's $640 million settlement with every state attorney general?
February 16, 2022
Cities, Tribes, Schools Fight Toss Of McKinsey Opioid MDL

Cities, Native American tribes, schools and state subdivisions have pushed back against a bid by McKinsey & Co. Inc. to dismiss multidistrict litigation alleging the company's aggressive marketing strategies fueled the opioid epidemic, saying a settlement between the states and the company shouldn't block their claims.
January 04, 2022
Opioid Claims Involving McKinsey Should Be Axed, States Say

A group of states is arguing that a California federal court should throw out claims from local governments in multidistrict litigation over consulting giant McKinsey & Co.'s alleged role in the opioid crisis.
August 20, 2021
Meet The Top Attys Battling McKinsey In New Opioid MDL

In the second multidistrict litigation over the opioid crisis, McKinsey & Co. will lock horns with veterans of the first opioid MDL as well as a BigLaw alumnus who launched a firm devoted to his pioneering litigation against the consulting powerhouse.
July 29, 2021
McKinsey Opioid MDL Has A Need For Speed, Judge Says

A California federal judge fired a proverbial starting pistol Thursday in multidistrict litigation over consulting giant McKinsey & Co.'s alleged role in the opioid crisis, telling attorneys at the MDL's first hearing to lace up their "track shoes" and expect swift rulings on pivotal threshold issues.